Haiying Zhang Selected Research

CU06-1004

1/2022	CU06-1004 enhances vascular integrity and improves cardiac remodeling by suppressing edema and inflammation in myocardial ischemia-reperfusion injury.
1/2021	Correction: The endothelial dysfunction blocker CU06-1004 ameliorates choline-deficient L-amino acid diet-induced non-alcoholic steatohepatitis in mice.
1/2020	CU06-1004 (endothelial dysfunction blocker) ameliorates astrocyte end-feet swelling by stabilizing endothelial cell junctions in cerebral ischemia/reperfusion injury.
1/2020	The endothelial dysfunction blocker CU06-1004 ameliorates choline-deficient L-amino acid diet-induced non-alcoholic steatohepatitis in mice.
1/2020	CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment via Cytotoxic T Cells.
1/2020	CU06-1004 Alleviates Experimental Colitis by Modulating Colonic Vessel Dysfunction.
1/2017	Sac-1004, a vascular leakage blocker, reduces cerebral ischemia-reperfusion injury by suppressing blood-brain barrier disruption and inflammation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Haiying Zhang Research Topics

Disease

38	Neoplasms (Cancer) 01/2022 - 04/2003
15	Inflammation (Inflammations) 10/2022 - 01/2013
12	Type 2 Diabetes Mellitus (MODY) 10/2022 - 02/2006
12	Metabolic Syndrome (Dysmetabolic Syndrome X) 07/2021 - 08/2011
10	Insulin Resistance 10/2021 - 01/2013
9	Ulcerative Colitis 01/2022 - 01/2016
7	Neoplasm Metastasis (Metastasis) 07/2021 - 06/2015
7	Infections 02/2019 - 05/2004
6	Glioma (Gliomas) 04/2021 - 01/2019
6	Non-alcoholic Fatty Liver Disease 06/2020 - 01/2013
6	Hyperglycemia 06/2019 - 08/2011
5	Osteosarcoma (Osteogenic Sarcoma) 01/2015 - 06/2012
4	Hypoxia (Hypoxemia) 10/2022 - 01/2018
4	Reperfusion Injury 01/2022 - 01/2017
4	Stroke (Strokes) 07/2021 - 10/2013
4	Fibrosis (Cirrhosis) 01/2020 - 01/2014
4	Erectile Dysfunction 01/2018 - 01/2012
4	Obesity 01/2018 - 10/2012
3	Leukemia 06/2022 - 11/2004
3	Pneumonia (Pneumonitis) 07/2021 - 10/2017
3	Urinary Bladder Neoplasms (Bladder Cancer) 07/2021 - 05/2016
3	Breast Neoplasms (Breast Cancer) 12/2020 - 06/2013
3	Herpes Zoster 01/2020 - 01/2017
3	Atherosclerosis 01/2020 - 03/2015
3	Necrosis 01/2019 - 02/2011
3	Hypertension (High Blood Pressure) 12/2018 - 02/2008
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2018 - 10/2013
3	Pain (Aches) 08/2011 - 01/2011
3	Opioid-Induced Constipation 08/2011 - 01/2011
3	Schizophrenia (Dementia Praecox) 09/2007 - 05/2004
2	COVID-19 07/2022 - 01/2022
2	Deglutition Disorders (Dysphagia) 07/2021 - 10/2020
2	Melanoma (Melanoma, Malignant) 02/2021 - 01/2017
2	Alcoholic Fatty Liver 01/2021 - 01/2020
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2021 - 01/2020
2	Ischemia 02/2020 - 01/2020
2	Brain Ischemia (Cerebral Ischemia) 01/2020 - 01/2017
2	Colitis 01/2020 - 01/2016
2	Atherosclerotic Plaque (Atheroma) 01/2020 - 01/2018
2	Adenocarcinoma of Lung 04/2019 - 03/2016
2	Chronic Hepatitis (Chronic Active Hepatitis) 02/2019 - 01/2014

Drug/Important Bio-Agent (IBA)

12	Biomarkers (Surrogate Marker)IBA 10/2022 - 09/2008
11	Proteins (Proteins, Gene)FDA Link 01/2022 - 06/2003
10	Testosterone (Sustanon)FDA Link 12/2018 - 01/2012
9	tofacitinibIBA 01/2022 - 01/2016
8	Glucose (Dextrose)FDA LinkGeneric 10/2022 - 10/2012
8	Pharmaceutical PreparationsIBA 01/2021 - 04/2005
7	CU06-1004IBA 01/2022 - 01/2017
7	LipidsIBA 01/2020 - 10/2012
7	CytokinesIBA 01/2020 - 05/2004
7	DNA (Deoxyribonucleic Acid)IBA 06/2014 - 06/2003
6	OsteocalcinIBA 01/2018 - 08/2011
6	Farnesyltranstransferase (Farnesyltransferase)IBA 11/2005 - 04/2003
5	Interleukin-6 (Interleukin 6)IBA 10/2022 - 05/2004
5	Janus Kinase InhibitorsIBA 01/2022 - 01/2017
5	Insulin (Novolin)FDA Link 10/2021 - 01/2013
5	Biological ProductsIBA 07/2021 - 12/2007
5	C-Reactive ProteinIBA 03/2020 - 02/2012
5	CholesterolIBA 12/2019 - 10/2012
5	Arsenic Trioxide (Trisenox)FDA Link 09/2016 - 06/2012
4	LipopolysaccharidesIBA 10/2022 - 08/2008
4	Antiviral Agents (Antivirals)IBA 07/2022 - 03/2014
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 04/2005
4	HDL CholesterolIBA 05/2020 - 08/2011
4	Therapeutic UsesIBA 01/2020 - 03/2016
3	Interleukin-2 (IL2)IBA 01/2022 - 01/2013
3	Janus KinasesIBA 06/2020 - 03/2016
3	IronIBA 06/2020 - 12/2019
3	Uric Acid (Urate)IBA 01/2020 - 01/2013
3	RNA (Ribonucleic Acid)IBA 11/2019 - 01/2014
3	Triglycerides (Triacylglycerol)IBA 05/2017 - 01/2013
3	Ferritins (Ferritin)IBA 01/2017 - 01/2014
3	Immunoglobulin E (IgE)IBA 01/2017 - 08/2013
3	Gonadal Steroid Hormones (Sex Hormones)IBA 05/2015 - 07/2013
3	methylnaltrexone FDA Link 08/2011 - 01/2011
2	Interleukin-17 (Interleukin 17)IBA 10/2022 - 01/2016
2	Oxygen (Dioxygen)IBA 10/2022 - 11/2017
2	Indicators and Reagents (Reagents)IBA 10/2021 - 01/2017
2	AndrogensIBA 10/2021 - 01/2013
2	MetalsIBA 07/2021 - 06/2020
2	Circular RNAIBA 04/2021 - 09/2020
2	Retinoic Acid Receptors (Retinoic Acid Receptor)IBA 01/2021 - 02/2020
2	CalciumIBA 01/2021 - 12/2019
2	Choline (Choline Chloride)IBA 01/2021 - 01/2020
2	Amino Acids FDA Link 01/2021 - 01/2020
2	Conditioned Culture MediaIBA 02/2020 - 10/2019
2	Immunoglobulins (Immunoglobulin)IBA 01/2020 - 07/2019
2	Nicotine FDA Link 01/2020 - 01/2018
2	Apolipoproteins E (ApoE)IBA 01/2020 - 01/2018
2	Complement System Proteins (Complement)IBA 12/2019 - 01/2016
2	Blood Glucose (Blood Sugar)IBA 06/2019 - 01/2017
2	Tyrosine Kinase InhibitorsIBA 04/2019 - 03/2016
2	Immunoglobulin M (IgM)IBA 02/2019 - 01/2012
2	AntigensIBA 02/2019 - 01/2014
2	Tumor Necrosis Factor InhibitorsIBA 01/2019 - 01/2017

Therapy/Procedure

22	Therapeutics 01/2022 - 02/2005
2	Enteral Nutrition (Feeding, Tube) 01/2022 - 07/2021
2	Drug Therapy (Chemotherapy) 12/2021 - 12/2014
2	Immunotherapy 01/2020 - 03/2016
2	Ligation 01/2020 - 10/2015